Disclosure of Business Responsibility and Sustainable Reporting (BRSR) of the Top Indian Pharmaceutical Industries with a New Approach
新しいアプローチによるインド主要製薬企業のビジネス責任と持続可能性報告（BRSR）の開示 (AI 翻訳)
Yudhistra Kumar Alavandar
🤖 gxceed AI 要約
日本語
本論文はインドの主要製薬4社のBRSR（ビジネス責任と持続可能性報告）開示をレビュー。環境・社会・経済（ESE）の3側面から9原則の遵守状況を分析し、ブランド価値と市場価値向上への寄与を指摘する。
English
This paper reviews the BRSR (Business Responsibility and Sustainable Reporting) disclosures of the top four Indian pharmaceutical companies. It analyzes compliance with nine principles from environmental, social, and economic (ESE) perspectives, highlighting potential brand value and market value improvements.
Unofficial AI-generated summary based on the public title and abstract. Not an official translation.
📝 gxceed 編集解説 — Why this matters
日本のGX文脈において
インドのBRSRは日本のSSBJと同様に企業の持続可能性開示を義務付ける枠組みであり、日本企業がインド市場やサプライチェーンを考慮する際の参考となる。
In the global GX context
BRSR is India's emerging sustainability reporting framework under SEBI. This paper offers a practical view of how leading Indian pharma firms disclose ESG information, useful for global investors and companies comparing disclosure practices across jurisdictions.
👥 読者別の含意
🔬研究者:Provides a baseline case study of BRSR implementation in the Indian pharma sector, useful for comparative disclosure research.
🏢実務担当者:Offers examples of how peer companies structure BRSR reports; can guide compliance or benchmarking.
🏛政策担当者:Highlights areas where BRSR principles are well-addressed or lacking, informing future regulatory refinement.
📄 Abstract（原文）
The top pharmaceutical companies play a vital role in contributing to the global drug manufacturing facility, which not only helps supplying drugs to the Indian market, which is third highest volume manufacturer of drugs in the world. India supplies 40 and 20 % of generic drugs to USA and UK. It is very important that the pharmaceutical companies in India take the highest responsibility towards protecting the Environment, Sociological and Economical (ESE) approach for following the nine principles of the Business Responsibility and Sustainability Approach (BRSR). We have reviewed the top four pharmaceutical companies for their disclosures for the BRSR with the new approach. The review revealed that principle two and six delas with environmental activity, whereas principle three to five, seven to eight, which deals with the sociological and economical aspect, principles one and nine, deals with the economic activity. Such type of disclosures will help us to create the brand value and increases the market value of the manufactured drugs in India and globally. We can know the current services, which they have provided to the society and various ways in which we will protect the environmental at large. There is many published information on the environmental, sustainable goals (ESG) but there is very less information about the ESE approach of the approach, which shows the disclosures of the pharmaceutical industry.
🔗 Provenance — このレコードを発見したソース
- semanticscholar https://research-advances.org/index.php/RAJMSS/article/download/2029/1467first seen 2026-07-13 06:50:19
🔔 こうした論文の新着を逃したくない方は キーワードアラート に登録（無料・3キーワードまで）。
gxceed は公開メタデータに基づく研究支援データセットです。要約・翻訳・解説は AI 支援で生成されています。 最終的な解釈・検証は利用者が原典資料に基づいて行うことを前提とします。